Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normoxic Allogenic UCMSC in severe COVID-19
NCT05132972Phase 3Unknown
- Sponsor
- National Research and Innovation Agency
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of normoxic allogenic UCMSC in coronavirus disease 2019 (COVID-19), sponsored by National Research and Innovation Agency. Status: unknown.
02
Drugs
normoxic allogenic UCMSC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05132972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132972.